Those folks with the Apo A1 milano variation seem ripe for further study of the beneficial HDL hypothesis---assuming their cardiovascular risk is really lower, which seems simple to verify.
If I recall correctly, the IP associated with therapeutic use of Apo A1 Milano still resides in the sub-basement of Pfizer as a result of the Esperion purchase?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.